Tyra Biosciences adds operations and regulatory veterans to accelerate precision medicine pipeline

Tyra Biosciences, Inc., a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced the appointment of two key members of its leadership team: Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer.  Together, Mr. Ashar and Ms. Faulds will be essential in advancing oral dabogratinib through global Phase 2 studies in skeletal dysplasia and urologic cancers and preparing for potential future pivotal Phase 3 studies. Mr. Ashar's appointment is effective immediately and Ms. Faulds's appointment is effective December 8, 2025.

"Bhavesh and Heather are joining TYRA at a defining moment, as what we are building carries profound significance," said Todd Harris, CEO of TYRA. "Our team is united by a shared belief that patients are counting on us to deliver the precision medicines of the future — oral therapies that are thoughtfully engineered, clinically meaningful, and capable of changing lives. Bhavesh and Heather bring not only deep expertise across oncology and rare disease development, regulatory strategy and commercialization, but also a genuine commitment to that mission. I'm grateful to welcome them to TYRA and excited for what we will accomplish together for patients."

"I am excited to join TYRA at this pivotal time to help shape the next phase of growth for the company," said Bhavesh Ashar, Chief Operating Officer.  "Throughout my career in oncology and rare disease, I've seen how targeted medicines can profoundly impact patients' lives.  I believe we have a tremendous opportunity with oral dabogratinib to deliver best-in-class medicines in both skeletal dysplasias and urologic cancers by selectively targeting FGFR3.  I look forward to partnering with this talented team to build a world-class organization capable of delivering transformative therapies to patients who need them most."